Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations.
نویسنده
چکیده
منابع مشابه
The appropriate omalizumab patient.
Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti-immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit ...
متن کاملThe anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 microg daily of beclomethasone dipropionate), were randomized to receive double-blind eithe...
متن کاملRhinoviruses, allergic inflammation, and asthma.
Viral infections affect wheezing and asthma in children and adults of all ages. In infancy, wheezing illnesses are usually viral in origin, and children with more severe wheezing episodes are more likely to develop recurrent episodes of asthma and to develop asthma later in childhood. Children who develop allergen-specific immunoglobulin E (allergic sensitization) and those who wheeze with huma...
متن کاملComparative Study of Immunological and Structural Properties of Two Recombinant Vaccine Candidates against Botulinum Neurotoxin Type E
Background: Recently, botulinum neurotoxin (BoNT)-derived recombinant proteins have been suggested as potential botulism vaccines. Here, with concentrating on BoNT type E (BoNT/E), we studied two of these binding domain-based recombinant proteins: a multivalent chimer protein, which is composed of BoNT serotypes A, B and E binding subdomains, and a monovalent recombinant protein, which contains...
متن کاملAssociation between Anti-IgA Antibody and Development of Adverse Reactions in Immunodeficient Patients Under Immunoglobulin Therapy
Background: Mild to severe post-transfusion adverse reactions have been reported in a proportion of immunodeficient patients receiving intravenous immunoglobulin (IVIg). Anti-IgA antibody has been proposed to be associated with development of such reactions. Objective: To assess the association between anti-IgA levels of different isotypes and adverse reactions induced in immunodeficient patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The European respiratory journal
دوره 18 2 شماره
صفحات -
تاریخ انتشار 2001